|Start:||Jul 18, 2022 - 10:00 am|
|End:||Jul 18, 2022 - 12:00 am|
|Venue:||IMDEA Nanociencia conference room and online.|
Place: IMDEA Nanociencia conference room and online.
Medicine is taking its first steps towards patient-specific cancer care. Nanoparticles have many potential benefits for treating cancer, including the ability to transport complex molecular cargoes including siRNA and protein, as well as targeting to specific cell populations.
The talk will discuss ‘barcoded nanoparticles’ that target sites of cancer where they perform a programmed therapeutic task. Specifically, liposomes that diagnose the tumor and metastasis for their sensitivity to different medications, providing patient-specific drug activity information that can be used to improve the medication choice.
The talk will also describe how liposomes can be used for degrading the pancreatic stroma to allow subsequent drug penetration into pancreatic adenocarcinoma, and how nanoparticle’ biodistribution and anti-cancer efficacy is impacted by patient’ sex and more specifically, the menstrual cycle.
The evolution of drug delivery systems into synthetic cells, programmed nanoparticles that have an autonomous capacity to synthesize diagnostic and therapeutic proteins inside the body, and their promise for treating cancer and immunotherapy, will be discussed.
1) Theranostic barcoded nanoparticles for personalized cancer medicine, Yaari et al. Nature Communications, 2016, 7, 13325
2) Collagenase nanoparticles enhance the penetration of drugs into pancreatic tumors, Zinger et al., ACS Nano, 13 (10), 11008-11021, 2019
3) Targeting neurons in the tumor microenvironment with bupivacaine nanoparticles reduces breast cancer progression and metastases, Science Advances, Kaduri et al., 7 (41), eabj5435, 2021
4) Nanoparticles accumulate in the female reproductive system during ovulation affecting cancer treatment and fertility, Poley et al., ACS nano, 2022.
Avi Schroeder is a tenured Associate Professor of Chemical Engineering at the Technion – Israel Institute of Technology, where he heads the Laboratory for Targeted Drug Delivery and Personalized Medicine Technologies (https://www.schroederlab.com/ ).
Dr. Schroeder conducted his Postdoctoral studies at the Massachusetts Institute of Technology, and his PhD jointly at the Hebrew and Ben Gurion Universities.
Avi is the recipient of more than 30 national and international awards, including named a KAVLI Fellow, the Intel Nanotechnology-, TEVA Pharmaceuticals-, and the Wolf Foundation Krill Awards. Avi is the author of above 50 research papers inventor of 19 patents and co-founder of multiple startup companies based on these discoveries.
Schroeder is a member of Israel Young National Academy of Sciences, Israel’s National Council for Civilian Research and Development, and the President of the Israel Institute of Chemical Engineers.
About IMDEA Nanociencia
IMDEA Nanociencia is a non-profit Foundation created on November 23rd 2006 by initiative of the regional Government of the Community of Madrid in November 2006 in order to shorten the distance between the research and society in the Madrid region and provide new capacity for research, technological development and innovation in the field of Nanoscience, Nanotechnology and Molecular Design. In 2007 the former Ministry of Education and Science of the Government of Spain decided to also fund part of the creation and equipment of an institute of Nanoscience in the Community of Madrid.
The Foundation manages the IMDEA Nanociencia Institute, a new interdisciplinary research Centre dedicated to the exploration of nanoscience and the development of applications of nanotechnology in connection with innovative industries. The IMDEA Nanociencia Institute is part of one of the strategic lines of the Campus of International Excellence (CEI) UAM+CSIC.